Thiogenesis Therapeutics is a clinical-stage biotechnology company developing advanced sulfur-based compounds, classified as thiols, to target oxidative stress and inflammation; key drivers of mitochondrial disease.
TTI-0102, a prodrug of cysteamine, enhances delivery flexibility, bioavailability, and tolerability, overcoming the limitations of past thiol-based drugs. Early clinical data indicates TTI-0102 is well tolerated at high doses.
Now in Phase 2, TTI-0102 is being studied in MELAS, Leigh syndrome spectrum, and other pediatric conditions.